tbuckley/cabot-search huggingface dataset:
Improving Safety Culture—To Err Is Human
Authors: Robert M. Van Haren, Shimul A. Shah
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Overexpression of Calreticulin Impairs Self-Renewal Capacity of Hematopoietic Stem Cells
Authors: Stefan Brooks, Sarah Morse, Brianna Craver, Hew Yeng Lai, Thanh Kim Nguyen, Daniel Kim, Angela G. Fleischman, Prasanthi Tata, Nilamani Jena, Zhong-Ying Liu, Richard A. Van Etten
Journal: Blood (2017)
Response to: ‘Glucosamine and mortality: a note of caution’ by Conway
Authors: Zhi-Hao Li, Qing-Mei Huang, Wen-Fang Zhong, Xi-Ru Zhang, Chen Mao
Journal: Annals of the Rheumatic Diseases (2020)

Response to: 'Glucosamine and mortality: a note of caution' by ConwayWe appreciate the comments by Conway 1 on our manuscript which investigated the association of regular glucosamine use with all-cause and cause-specific mortality. 2irst, we agree that the underlying mechanisms, including inhibition of nuclear factor-κB thereby reducing inflammation and glucosamine triggering a mimic response of low carbohydrate diet, might partially explain the association between glucosamine use and mortality.Future studies are needed to better understand underlying pharmacological roles of glucosamine on health outcomes.Second, the association of mortality with glucosamine use might be confused by unmeasured underlying lifestyle-related factors or other confounders.Nevertheless, in our analyses, we had carefully adjusted for several important confounders, including sociodemographic factors, lifestyle behaviours, health status, drug use and other supplements use.In total, 27 confounders were included in our fully adjusted models, and the adjustment for confounding was sufficient.Third, randomised controlled trial (RCT) is indeed the ideal study design to clarify these issues.However, most previous RCTs, investigating the association between glucosamine use and health outcomes, mainly focused on the therapy in treating patients with osteoarthritis or other chronic diseases, 3-5 who might have relatively poorer prognoses than healthy people in primary prevention trials.Moreover, several previous largescale cohort studies found the similar magnitude of benefit of glucosamine on mortality, [6][7][8] which are generally consistent with our study.Therefore, in the absence of sufficient sample size and sufficient trail duration, it might be difficult for previous RCTs to find such magnitude of benefit of glucosamine.Further studies are necessary to better clarify the association between glucosamine use and mortality.
Combination therapy of vitamin C and thiamine for septic shock: a multi-centre, double-blinded randomized, controlled study
Authors: Sung Yeon Hwang, Seung Mok Ryoo, Jong Eun Park, You Hwan Jo, Dong-Hyun Jang, Gil Joon Suh, Taegyun Kim, Youn-Jung Kim, Seonwoo Kim, Hyun Cho, Ik Joon Jo, Sung Phil Chung, Sung-Hyuk Choi, Tae Gun Shin, Won Young Kim
Journal: Intensive Care Medicine (2020)
Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic
Authors: Edward Christopher Dee, Brandon A. Mahal, Melaku A. Arega, Anthony V. D’Amico, Kent W. Mouw, Paul L. Nguyen, Vinayak Muralidhar
Journal: JAMA Oncology (2020)

This cohort study uses National Cancer Database data from 2004 to 2014 to examine the association between overall survival and timing of radiotherapy relative to androgen deprivation therapy in patients with prostate cancer.
Implications for technological reserve development in advancing age, cognitive impairment, and dementia
Authors: Jared F. Benge, Michael K. Scullin
Journal: Behavioral and Brain Sciences (2020)

Abstract This commentary draws connections between technological culture emergence and recent trends in using assistive technology to reduce the burden of Alzheimer's disease. By the technical-reasoning hypothesis, cognitively-impaired individuals will lack the cognitive ability to employ technologies. By the technological reserve hypothesis, social-motivational and cultural transmissibility factors can provide foundations for using technology as cognitive prosthetics even during neurodegenerative illnesses.
Abstract 15047: Impact of Co-Existing Chronic Obstructive Pulmonary Disease versus Obesity Hypoventilation Syndrome (Pickwickian Syndrome) on In-Hospital Outcomes of Percutaneous Coronary Interventions in Patients With Obstructive Sleep Apnea
Authors: Rupak Desai, Upenkumar Patel, Rushik Bhuva, Tarang Parekh, Sonu Gupta, Yash Varma, Muhammad Uzair Lodhi, Mir Z Khan, Nazia Farheen, Rajesh Sachdeva, Gautam Kumar
Journal: Circulation (2019)

Background: Patients with obstructive sleep apnea (OSA) are known to experience worse cardiovascular outcomes following percutaneous coronary interventions (PCI). However, the impact of frequent co...
ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1
Authors: Yunhao Chen, Yanchun Zhao, Junru Chen, Chuanhui Peng, Yanpeng Zhang, Rongliang Tong, Qiyang Cheng, Beng Yang, Xiaode Feng, Yuejie Lu, Haiyang Xie, Lin Zhou, Jian Wu, Shusen Zheng
Journal: Molecular Cancer (2020)

Abstract Background N6-methyladenosine (m 6 A) modification is an emerging layer of epigenetic regulation which is widely implicated in the tumorigenicity of hepatocellular carcinoma (HCC), offering a novel perspective for investigating molecular pathogenesis of this disease. The role of AlkB homolog 5 (ALKBH5), one of the m 6 A demethylases, has not been fully explored in HCC. Here we clarify the biological profile and potential mechanisms of ALKBH5 in HCC. Methods Expression of ALKBH5 and its correlation with clinicopathological characteristics of HCC were evaluated using tissue microarrays and online datasets. And biological effects of ALKBH5 in HCC were determined in vitro and in vivo. Subsequently, methylated RNA immunoprecipitation sequencing (MeRIP-seq) combined with RNA sequencing (RNA-seq), and following m 6 A dot blot, MeRIP-qPCR, RIP-qPCR or dual luciferase reporter assays were employed to screen and validate the candidate targets of ALKBH5. Results We demonstrated that ALKBH5 was down-regulated in HCC, and decreased ALKBH5 expression was an independent prognostic factor of worse survival in HCC patients. Functionally, ALKBH5 suppressed the proliferation and invasion capabilities of HCC cells in vitro and in vivo. Mechanistically, ALKBH5-mediated m 6 A demethylation led to a post-transcriptional inhibition of LY6/PLAUR Domain Containing 1 (LYPD1), which could be recognized and stabilized by the m 6 A effector IGF2BP1. In addition, we identified that LYPD1 induced oncogenic behaviors of tumors in contrast to ALKBH5. Dysregulation of ALKBH5/LYPD1 axis impelled the progression of HCC. Conclusion Our study reveals that ALKBH5, characterized as a tumor suppressor, attenuates the expression of LYPD1 via an m 6 A-dependent manner in HCC cells. Our findings enrich the landscape of m 6 A-modulated tumor malignancy, and provide new insights into potential biomarkers and therapeutic targets of HCC treatment.
Targeted Intraoperative Radiotherapy for Early Breast Cancer
Authors: Chirag Shah, David Wazer, Frank Vicini
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus
Authors: Fanny Saidoune, Guillaume Even, Yasmine Lamri, Julie Chezel, Anh‐Thu Gaston, Brigitte Escoubet, Thomas Papo, Nicolas Charles, Antonino Nicoletti, Karim Sacre
Journal: Arthritis & Rheumatology (2020)

Cardiovascular disease (CVD) is the leading cause of death in systemic lupus erythematosus (SLE). B cells play a key role in the pathogenesis of lupus, and anti-BAFF therapy has been approved for use in SLE. Since mature B cells also promote atherosclerosis, we undertook this study to evaluate, in a mouse model and in SLE patients, whether BAFF neutralization has an atheroprotective effect in SLE.The effect of BAFF on atherosclerosis associated with lupus was investigated in the atherosclerosis/lupus-prone apolipoprotein E-knockout D227K mouse model and in a cohort of SLE patients. Mice were treated with a blocking anti-BAFF monoclonal antibody (mAb), while fed a standard chow diet. Carotid plaque and carotid intima-media thickness were assessed by ultrasound at baseline and during follow-up in SLE patients who were asymptomatic for CVD.Anti-BAFF mAb in ApoE-/- D227K mice induced B cell depletion, efficiently treated lupus, and improved atherosclerosis lesions (21% decrease; P = 0.007) in mice with low plasma cholesterol levels but worsened the lesions (17% increase; P = 0.06) in mice with high cholesterol levels. The atheroprotective effect of the BAFF-BAFF receptor signaling inhibition on B cells was counterbalanced by the proatherogenic effect of the BAFF-TACI signaling inhibition on macrophages. In SLE patients, blood BAFF levels were associated with subclinical atherosclerosis (r = 0.26, P = 0.03). Anti-BAFF mAb treatment had a differential effect on the intima-media thickness progression in SLE patients depending on body mass index.Depending on the balance between lipid-induced and B cell-induced proatherogenic conditions, anti-BAFF could be detrimental or beneficial, respectively, to atherosclerosis development in SLE.
In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States
Authors: Stephen J. Greene, Taylor S. Triana, Raluca Ionescu-Ittu, Rebecca M. Burne, Annie Guérin, Maria Borentain, Paul D. Kessler, Aylin Tugcu, Mary M. DeSouza, G. Michael Felker, Lei Chen
Journal: JACC Heart Failure (2020)
Tailored core‒shell dual metal–organic frameworks as a versatile nanomotor for effective synergistic antitumor therapy
Authors: Biyuan Wu, Jintao Fu, Yixian Zhou, Sulan Luo, Yiting Zhao, Guilan Quan, Xin Pan, Chuanbin Wu
Journal: Acta Pharmaceutica Sinica B (2020)

Malignant tumor has become an urgent threat to global public healthcare. Because of the heterogeneity of tumor, single therapy presents great limitations while synergistic therapy is arousing much attention, which shows desperate need of intelligent carrier for co-delivery. A core‒shell dual metal–organic frameworks (MOFs) system was delicately designed in this study, which not only possessed the unique properties of both materials, but also provided two individual specific functional zones for co-drug delivery. Photosensitizer indocyanine green (ICG) and chemotherapeutic agent doxorubicin (DOX) were stepwisely encapsulated into the nanopores of MIL-88 core and ZIF-8 shell to construct a synergistic photothermal/photodynamic/chemotherapy nanoplatform. Except for efficient drug delivery, the MIL-88 could be functioned as a nanomotor to convert the excessive hydrogen peroxide at tumor microenvironment into adequate oxygen for photodynamic therapy. The DOX release from [email protected] nanoparticles was triggered at tumor acidic microenvironment and further accelerated by near-infrared (NIR) light irradiation. The in vivo antitumor study showed superior synergistic antitumor effect by concentrating the nanoparticles into dissolving microneedles as compared to intravenous and intratumoral injection of nanoparticles, with a significantly higher inhibition rate. It is anticipated that the multi-model synergistic system based on dual-MOFs was promising for further biomedical application.
High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes
Authors: Olive Tang, Kunihiro Matsushita, Josef Coresh, Chiadi Ndumele, John W. McEvoy, A. Richey Sharrett, Ron Hoogeveen, Christie M. Ballantyne, Elizabeth Selvin
Journal: Diabetes Care (2020)

New therapeutics for cardiovascular disease (CVD) prevention in diabetes are costly, highlighting the need for better risk stratification so that interventions may be targeted to those at the highest risk. High-sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) are measures of subclinical cardiac damage associated with cardiovascular risk in the general population (1,2). The troponins appear differentially associated with diabetes (3). We assessed whether hs-cTnI or hs-cTnT could improve cardiovascular and mortality risk stratification in adults with diabetes and whether elevated concentrations of either troponin (≥90th percentile) were associated with mortality risk similar to those having a history of clinical CVD.

We included 1,704 adults (ages 54–75 years) with diabetes (47.5% of whom were male, 33.8% Black, and 24.4% with CVD) in the Atherosclerosis Risk in Communities (ARIC) study who attended visit 4 (1996–1998). Diabetes status was defined based on self-reported physician diagnosis, medication use, or blood glucose (fasting ≥126 mg/dL; nonfasting ≥200 mg/dL).

hs-cTnI was measured in stored plasma using the ARCHITECT STAT High Sensitive Troponin-I assay (Abbott Diagnostics, Chicago, IL). hs-cTnT was measured in stored plasma using the Elecsys Troponin T assay (Roche Diagnostics, Indianapolis, IN). To compare hs-cTnI and hs-cTnT, we used percentile categories among those without CVD: <50th (reference), ≥50th to <75th, 75th to 90th, and ≥90th.

We examined incident CVD ( N = 1,280): atherosclerotic CVD (ASCVD) (including myocardial infarction, revascularization procedure, or stroke) and heart failure (based on hospitalization, supplemented with adjudicated events after 2005) (4,5). The last date of follow-up was 31 December 2018 (median follow-up 19 years).

We used Cox regression …
Abstract 10932: PCSK9 Inhibitor Exerts Neuroprotective Effects Following Cardiac Ischemia-Reperfusion Injury
Authors: Dalila M Moisescu, Nattayaporn Apaijai, Siripong Palee, Christian M McSweeney, Chayodom Maneechote, Chiraphat Boonnag, Nipon Chattipakorn, Siriporn C Chattipakorn
Journal: Circulation (2018)

Introduction: Cardiac ischemia/reperfusion (I/R) injury led not only to a reduction in cerebral blood flow, but also brain mitochondrial dysfunction, microglial hyperactivity and reduced dendritic ...
Elemene, a novel plant anticancer drug, enhances cisplatin cell killing effects in resistant and sensitive NSCLC cell lines via p53-dependent and -independent apoptotic pathways
Authors: Gangduo Wang, Jinshun Zhao, Xiping Li, Hong Ding, Cynthia Cunningham, Daniel Flynn, Eddie Reed, Qingdi Q. Li
Journal: Cancer Research (2005)

4123  For more than two decades, the most effective systemic chemotherapy for NSCLC was based on cisplatin combinations. However, currently available cisplatin-based chemotherapy for lung cancer is only a narrow therapeutic window between efficacy and unacceptable toxicity. Therefore, there is a need to develop new strategies to treat this disease effectively. Our recent studies showed that elemene, a novel low adverse effect anticancer drug extracted from the ginger plant, triggered NSCLC cell death and increased NSCLC cells sensitivity to cisplatin. However, the precise mechanisms of elemene-inhibited cell proliferation and increased cisplatin sensitivity in NSCLC are largely unknown. This study investigated the ability of elemene and cisplatin to induce apoptosis in p53 wild-type, mutant and null NSCLC cell lines and the underlying mechanisms. We showed that elemene has an effect on cell-killing in the human NSCLC cell lines H460, H23, and H358. Elemene was also found to increase cisplatin cytotoxicity and significantly augment cisplatin sensitivity in all of these cell lines, particularly in H358, a p53 null and native cisplatin resistant cell line. Moreover, we demonstrated, by using FACS analysis with Annexin V staining, Cell Death Detection ELISA Kit and the mitochondrial membrane potential assay, that elemene or cisplatin independently induced apoptosis in these systems in a time- and dose-dependent manner, and that a synergistic effect in this regard was seen when cells were treated with both agents. Further studies clearly showed that these treatments (elemene, cisplatin alone, or in combination) induced increases in caspase-9, -8, -3, -7 and -10 activities, Bax expression, and Bcl-2 phosphorylation, decreased levels of Bcl-2 and XIAP proteins, caused cytochrome c release from the mitochondria, and increased levels of cleaved caspase-9 and PARP in the three cell lines with different p53 status. In addition, introducing wild-type p53 into p53 null H358 cell line and silencing p53 by siRNA in p53 wild-type cell line H460 differentially affected apoptotic response to elemene, cisplatin, or combination treatments. Together, these findings suggest that elemene may augment sensitivity and reverse drug resistance to cisplatin in human NSCLC through p53-dependent and -independent apoptotic pathways. This study was supported by NIH/NCRR grant P20 RR16440.
Component‐resolved microarray analysis of IgE sensitization profiles to <i>Culicoides</i> recombinant allergens in horses with insect bite hypersensitivity
Authors: Ella N. Novotny, Samuel J. White, A. Douglas Wilson, Sara B. Stefánsdóttir, Edwin Tijhaar, Sigridur Jonsdóttir, Rebekka Frey, Dania Reiche, Horst Rose, Claudio Rhyner, Gertraud Schüpbach‐Regula, Sigurbjörg Torsteinsdóttir, Marcos Alcocer, Eliane Marti
Journal: Allergy (2020)

Allergy to bites of blood-sucking insects, including biting midges, can affect both human and veterinary patients. Horses are often suffering from an IgE-mediated allergic dermatitis caused by bites of midges (Culicoides spp). With the aim to improve allergen immunotherapy (AIT), numerous Culicoides allergens have been produced as recombinant (r-) proteins. This study aimed to test a comprehensive panel of differently expressed Culicoides r-allergens on a cohort of IBH-affected and control horses using an allergen microarray.IgE levels to 27 Culicoides r-allergens, including 8 previously unpublished allergens, of which 11 were expressed in more than one expression system, were determined in sera from 347 horses. ROC analyses were carried out, cut-offs selected using a specificity of 95% and seropositivity rates compared between horses affected with insect bite hypersensitivity (IBH) and control horses. The combination of r-allergens giving the best performing test was determined using logistic regression analysis.Seropositivity was significantly higher in IBH horses compared with controls for 25 r-allergens. Nine Culicoides r-allergens were major allergens for IBH with seven of them binding IgE in sera from > 70% of the IBH-affected horses. Combination of these top seven r-allergens could diagnose > 90% of IBH-affected horses with a specificity of > 95%. Correlation between differently expressed r-allergens was usually high (mean = 0.69, range: 0.28-0.91).This microarray will be a powerful tool for the development of component-resolved, patient-tailored AIT for IBH and could be useful for the study of allergy to biting midges in humans and other species.
High-Risk Infective Endocarditis in People Who Inject Drugs
Authors: Andrew J. Stewardson, Steven Y.C. Tong
Journal: JAMA Network Open (2020)

Charlie Tan, MD; Esfandiar Shojaei, MD; Joshua Wiener, BHSc; Meera Shah, BMSc; Sharon Koivu, MD; Michael Silverman, MD
A long view of cumulative technological culture
Authors: Michael J. O'Brien, R. Alexander Bentley
Journal: Behavioral and Brain Sciences (2020)

Abstract We agree that the emergence of cumulative technological culture was tied to nonsocial cognitive skills, namely, technical-reasoning skills, which allowed humans to constantly acquire and improve information. Our concern is with a reading of the history of cumulative technological culture that is based largely on modern experiments in simulated settings and less on phenomena crucial to the long-term dynamics of cultural evolution.
The type I interferon response in COVID-19: implications for treatment
Authors: Jeong Seok Lee, Eui-Cheol Shin
Journal: Nature reviews. Immunology (2020)

Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19. In this Comment, Jeong Seok Lee and Eui-Cheol Shin discuss contradictory results regarding the downregulation or upregulation of type I interferon responses in patients with COVID-19 and the implications for therapies that target this pathway.